Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798761 | 0.80 | ABCC8 (0.43) | ABCC8KCNJ11CA2 | |
| SCHEMBL7080930 | 0.73 | ABCC8 (0.40) | ABCC8KCNJ11 | |
| SCHEMBL8286612 | 0.60 | ABCC8 (0.50) | ABCC8KCNJ11CA2 | |
| SCHEMBL31379135 | 0.59 | MEN1 (0.34) | — | |
| SCHEMBL8625922 | 0.59 | ALDH1A1 (0.39) | ABCC8KCNJ11 | |
| Water SCHEMBL8624937 | 0.58 | ALDH1A1 (0.38) | ABCC8KCNJ11 | |
| SCHEMBL4266838 | 0.58 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL7565061 | 0.57 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL4260154 | 0.57 | ABCC8 (0.46) | ABCC8KCNJ11 | |
| SCHEMBL31379139 | 0.56 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | claimed |
| US-20020119969-A1 | Novel process | NOVO NORDISK A/S (DK) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119969-A1 | Novel process | CYP3A5, CYP4F2, CYP4F12 | ABCC8 2284/4885KCNJ11 1510/4885BACE1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.